The safety of the COX-2 inhibiting painkiller Celebrex® has been called into question by a recent study. That study, conducted by the National Cancer Institute, has shown that patients taking an 800 mg dose had 3.4 times greater risk of cardiovascular problems than those taking placebo. Patients taking the 400 mg dose showed 2.5 times greater risk as well.
This comes in the wake of the recall of a similar drug, Vioxx®. Both are part of a class of painkillers known as selective COX-2 inhibitors. There have also been several warnings by respected medical professionals involving this family of drugs. The New England Journal of Medicing recently published an article recommending that physicians stop prescribing the COX-2 inhibitor Bextra®. Both Bextra® and Celebrex® are products of the drug company Pfizer.
If you believe that you or a relative were injured by taking Celebrex® please use the form below to contact our law firm.
Copyright © 1999-2008 Specter Specter Evans & Manogue, P.C.
Terms of Use | Privacy Policy
Pfizer May Cut Jobs Due to Celebrex®
Celebrex® Will Carry New Warning In Australia
Public Citizen Says Pfizer Hid Celebrex® Study
Public Citizen Wants Celebrex® and Bextra® Off Market
Study Says Vioxx® & Celebrex® were Overprescribed
Pfizer is Pulling Celebrex® Ads
Celebrex® Prescriptions Decline
FDA Orders Review of Celebrex®
Celebrex® Implicated in Canadian Deaths
Health Canada Issues Celebrex® Warning
